- Home
- DNLI
as 07-26-2024 4:00pm EST
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.0B | IPO Year: | 2017 |
| Target Price: | $40.33 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.56 - $28.75 | Next Earning Date: | 08-06-2024 |
| Revenue: | $295,390,000 | Revenue Growth: | 191.13% |
| Revenue Growth (this year): | -85.19% | Revenue Growth (next year): | 125.76% |
Stock Insider Trading Activity of Denali Therapeutics Inc. (DNLI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SATO VICKI L | DNLI | Director | Jul 1 '24 | Sell | $22.86 | 100 | $2,286.00 | 119,256 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | Jul 1 '24 | Sell | $22.12 | 2,980 | $65,917.60 | 119,356 | SEC Form 4 |
| Cook Jennifer E. | DNLI | Director | Jun 6 '24 | Sell | $21.73 | 1,458 | $31,682.34 | 20,038 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | May 15 '24 | Sell | $20.39 | 1,674 | $34,132.86 | 116,369 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | Apr 15 '24 | Sell | $18.29 | 1,666 | $30,471.14 | 118,043 | SEC Form 4 |
| Krognes Steve E. | DNLI | Director | Apr 1 '24 | Sell | $20.50 | 92,500 | $1,896,250.00 | 47,341 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | Mar 15 '24 | Sell | $20.10 | 1,666 | $33,486.60 | 119,709 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | Feb 15 '24 | Sell | $18.37 | 1,666 | $30,604.42 | 121,375 | SEC Form 4 |
| Ho Carole | DNLI | Chief Medical Officer | Feb 13 '24 | Sell | $17.79 | 1,405 | $24,994.95 | 143,605 | SEC Form 4 |
| Ho Carole | DNLI | Chief Medical Officer | Feb 13 '24 | Sell | $17.29 | 2,784 | $48,135.36 | 145,010 | SEC Form 4 |
| Krognes Steve E. | DNLI | Director | Feb 13 '24 | Sell | $17.29 | 2,750 | $47,547.50 | 139,841 | SEC Form 4 |
| Watts Ryan J. | DNLI | President and CEO | Feb 13 '24 | Sell | $17.29 | 9,589 | $165,793.81 | 238,067 | SEC Form 4 |
| Schuth Alexander O. | DNLI | COFO and Secretary | Feb 13 '24 | Sell | $17.29 | 2,716 | $46,959.64 | 207,469 | SEC Form 4 |
| Schuth Alexander O. | DNLI | COFO and Secretary | Feb 13 '24 | Sell | $17.66 | 20,128 | $355,460.48 | 187,341 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | Jan 16 '24 | Sell | $18.42 | 1,666 | $30,687.72 | 123,041 | SEC Form 4 |
| Ho Carole | DNLI | Chief Medical Officer | Jan 10 '24 | Sell | $19.02 | 4,668 | $88,785.36 | 147,794 | SEC Form 4 |
| Watts Ryan J. | DNLI | President and CEO | Jan 9 '24 | Sell | $19.78 | 7,818 | $154,640.04 | 2,268,363 | SEC Form 4 |
| Ho Carole | DNLI | Chief Medical Officer | Jan 5 '24 | Sell | $19.43 | 9,972 | $193,755.96 | 198,777 | SEC Form 4 |
| Schuth Alexander O. | DNLI | COFO and Secretary | Jan 5 '24 | Sell | $19.43 | 9,972 | $193,755.96 | 539,307 | SEC Form 4 |
| Watts Ryan J. | DNLI | President and CEO | Jan 5 '24 | Sell | $19.43 | 17,483 | $339,694.69 | 2,276,181 | SEC Form 4 |
| Krognes Steve E. | DNLI | Director | Jan 5 '24 | Sell | $19.43 | 3,208 | $62,331.44 | 142,591 | SEC Form 4 |
| SATO VICKI L | DNLI | Director | Dec 15 '23 | Sell | $23.39 | 1,666 | $38,967.74 | 124,707 | SEC Form 4 |
Latest Denali Therapeutics Inc. News
DNLI Breaking Stock News: Dive into DNLI Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Investor's Business Daily
10 days ago
Denali Therapeutics Stock Gets Technical Rating Upgrade
Zacks
a month ago
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
Zacks
a month ago
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
Zacks
2 months ago
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Simply Wall St.
2 months ago
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Zacks
2 months ago
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Zacks
2 months ago
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
Compare DNLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNLI Denali Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.